Literature DB >> 26581921

Idarucizumab approved for reversal of anticoagulant effects of dabigatran.

Kate Traynor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26581921     DOI: 10.2146/news150077

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  1 in total

1.  Pharmacology: Dabigatran specific antidote.

Authors:  A Curto
Journal:  Br Dent J       Date:  2016-03-25       Impact factor: 1.626

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.